| Business: |
Note: EIR Biopharma, Inc. withdrew its plans for an IPO in a letter to the SEC on Nov. 16, 2026. The company filed its S-1 in February 2026.
(Incorporated in Delaware)
We are an early-stage biopharmaceutical company focused on developing therapeutics for the treatment of eye disease. Combined, our founders have more than 50 years of senior level management experience in the biotechnology, pharmaceutical, and biopharma industries, including leadership roles at Intercept Pharmaceuticals, Iovance Biotherapeutics, and GT Biopharma.
Our strategy is to negotiate worldwide exclusive licenses for the right to develop therapies for the treatment of eye disease; we target preclinical assets that promise to meet clear clinical needs and that can be advanced to a clinical stage with the investment of several million dollars over 14 to 18 months. Our principal preclinical assets have been licensed from prominent research institutions, including the Weill Cornell Medical College of Cornell University and the University of Miami.
Our Lead Product Candidates
EIR-0205 is a small molecule drug we licensed from Cornell University that we intend to develop for treatment of the atrophic “dry” form of age-related macular degeneration (dry AMD). EIR-0205 is a functionalized cyclodextrin designed to extract lipofuscin, a waste product that accumulates in the retinal epithelium causing degeneration of the retina leading to dry AMD. We are currently soliciting proposals from CROs for the activities necessary to enable submission of an Investigational New Drug (IND) application with the FDA, and currently plan to initiate human clinical studies in late 2027.
EIR-1003 is a peptidomimetic drug candidate licensed from the University of Miami, designed to mimic ephrin ligands. The signaling between Ephrin receptor and ephrin ligands regulates directional growth of retinal ganglion cell axons and dendrites to the vision center of the brain. Studies conducted at the University of Miami demonstrate that treatment with EIR-1003 increases nerve regeneration in animal models of optic nerve injury. We are advancing EIR-1003 into animal toxicology studies in order to file an IND with the FDA; we currently plan to initiate human clinical studies in early 2027.
We operate as a semi-virtual company, a common model for drug development companies that we believe reduces overhead costs. We rely on commercial contract research and development organizations for the conduct of toxicology evaluation in appropriate animal models of eye disease prior to administration of the drug candidates to humans in clinical trials. We also rely on commercial contract manufacturing organizations for the manufacture of our product candidates in compliance with Good Manufacturing Practices (GMP) and FDA guidelines.
Our Pipeline
We are advancing EIR-0205 and EIR-1003 into IND-enabling toxicological studies in animals in accordance with Good Laboratory Practice (GLP) guidelines, and into manufacturing and drug product formulation in accordance with GMP guidelines in anticipation of commencing Phase I clinical trials. We anticipate the Phase I studies will be conducted at the University of Miami’s Bascom Eye Institute.
Note: EIR Biopharma, Inc. has not generated any product revenue to date, according to the prospectus.
Note: Net loss is for the nine months that ended on Sept. 30, 2025, according to the prospectus.
Note: As of the date of the S-1 filing, EIR Biopharma had two part-time employees.
(Note: EIR Biopharma, Inc. withdrew its plans for its small IPO in a letter to the SEC on Nov. 16, 2026. The IPO had been planned as a listing on the NYSE-American Exchange (NYSE-AmEx), according to its SEC filings. Background: EIR Biopharma, Inc. filed its S-1 on Feb. 17, 2026, and disclosed the terms for its small IPO – 3.75 million shares at a price range of $4.00 to $5.00 – to raise $17 million, if priced at the $4.50 mid-point of its range. Note: The company had not selected a proposed symbol for its IPO, according to its S-1 filing.)
|